Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Non-Current Assets (2016 - 2026)

Sunshine Biopharma filings provide 11 years of Non-Current Assets readings, the most recent being $3.2 million for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 29.79% to $3.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.2 million, a 29.79% decrease, with the full-year FY2025 number at $3.2 million, down 29.79% from a year prior.
  • Non-Current Assets hit $3.2 million in Q4 2025 for Sunshine Biopharma, down from $3.5 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $4.7 million in Q1 2025 to a low of $1642.0 in Q2 2022.
  • Median Non-Current Assets over the past 5 years was $2.3 million (2023), compared with a mean of $2.1 million.
  • Biggest five-year swings in Non-Current Assets: tumbled 87.82% in 2022 and later soared 140662.06% in 2023.
  • Sunshine Biopharma's Non-Current Assets stood at $7061.0 in 2021, then surged by 27254.68% to $1.9 million in 2022, then grew by 27.2% to $2.5 million in 2023, then soared by 86.98% to $4.6 million in 2024, then fell by 29.79% to $3.2 million in 2025.
  • The last three reported values for Non-Current Assets were $3.2 million (Q4 2025), $3.5 million (Q3 2025), and $4.1 million (Q2 2025) per Business Quant data.